Compare Nike Inc (NKE) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Tenet Healthcare Corporation — how do they compare? Nike Inc trades at $34.96 (market cap $51.04B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Nike Inc is far larger — about 2.4× Tenet Healthcare Corporation's market cap, and Nike Inc pays a 4.77% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Tenet Healthcare Corporation for 15 Days on average.
| NKE | THC | |
|---|---|---|
Market Cap | $51.04B | $20.92B |
Volume | 37,567,242 | 455,764 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $280.77 |
52-Week Low | $33.87 | $161.37 |
Typical Hold Time | 155 Days | 15 Days |
Enterprise Value | $53.74B | $32.00B |
Dividend Yield | 4.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $34.74, up 0.38% on the day, amid a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 43.07% gross margin and 21.56% ROE, but revenue declined to $46.31B in 2025. Recent news highlights challenges in China and EMEA, while analysts maintain a $36.98 consensus target.
Nike's outlook hinges on executing its turnaround strategy to revive growth. Investment opportunities include brand strength and digital initiatives, but risks involve sluggish demand, margin pressure, and intense competition. The stock's valuation appears reasonable with a P/E of 16.44, yet near-term headwinds warrant caution.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
